Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study

2008685 citationsJournal Articlebronze Open Access

Authors

Weekly paclitaxel at the dose schedule used in the current study was well tolerated and demonstrated clinical benefit.

Good health and well-being

Published in: Journal of Clinical Oncology

Volume 26, Issue 32, pp. 5269-5274

Field-Weighted Citation Impact: 12.90